| Date |
|
Title |
| 06/10/10 |
|
Harbor BioSciences Announces Closing of $2.06 Million Equity Financing |
| 06/08/10 |
|
8-K Entry into a Material Definitive Agreement |
| 06/07/10 |
|
Harbor BioSciences Apoptone® for Prostate Cancer Shows Activity at All Doses Tested – Newest Phase I/IIa Data Presented at ASCO Annual Meeting |
| 06/07/10 |
|
Harbor BioSciences Announces $2.06 Million Equity Financing |
| 05/17/10 |
|
Harbor BioSciences Apoptone® Clinical Results Poster Selected for ASCO Annual Meeting |
| 05/10/10 |
|
Triolex® Demonstrates Evidence of Anti-Inflammatory Activity in a Phase IIa Clinical Trial in a Subset of Type 2 Diabetes Mellitus Patients |
| 03/30/10 |
|
Harbor BioSciences 10-K |
| 03/17/10 |
|
Harbor BioSciences Announces
Listing Transfer to The Nasdaq Capital Market |
| 03/17/10 |
|
8-K NASDAQ Approves Harbor BioSciences
Listing Transfer to The Nasdaq Capital Market |
| 03/08/10 |
|
Harbor BioSciences Reports New Phase I/IIa Data at ASCO Symposium and Announces Plans to Advance Prostate Cancer Treatment Apoptone® to Phase IIb |
| 03/05/10 |
|
8-K Apoptone Update Presentation |
| 03/01/10 |
|
Harbor BioSciences to Present Results on Lead Drug Candidate Apoptone® |
| 02/24/10 |
|
Harbor BioSciences to
Receive Patent for Apoptone® Cancer Treatment |
| 02/17/10 |
|
Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and
Ticker Symbol Change to ‘HRBR’ |
| 02/16/10 |
|
8-K Name Change |
| 11/16/09 |
|
Hollis-Eden Presents New Interim Data from Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference |
| 11/12/09 |
|
Hollis-Eden to Present Interim Data from its Phase I/II Clinical Studies of Apoptone® (HE3235) at Molecular Targets and Cancer Therapeutics Conference – Company Provides Update on Progress of Lead Compounds
|
| 10/22/09 |
|
8-K Plan Rights Amendment |
| 10/20/09 |
|
Hollis-Eden Pharmaceuticals Retains Burrill LLC to Provide Exclusive Advisory Services for Lead Programs |
| 09/16/09 |
|
Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price |
| 06/15/09 |
|
Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO |
| 03/31/09 |
|
Hollis-Eden Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results |
| 02/02/09 |
|
Hollis-Eden Pharmaceuticals Announces Cost-Cutting Measures to Focus Resources on Advancement of Ongoing Clinical Development Programs |
| 01/30/09 |
|
Hollis-Eden Pharmaceuticals to Present at 2009 BIO CEO and Investor Conference |
| 01/26/09 |
|
University of California San Diego Researchers Present Preclinical Data Demonstrating Benefits of TRIOLEX (HE3286) in Model of Obesity Induced Metabolic Disorders |
| 01/23/09 |
|
Hollis-Eden Researchers Present New Findings on Mechanism of Action for Anti-Cancer Drug Candidate APOPTONE(TM) (HE3235) at American Association of Cancer Research Meeting |
| 11/17/08 |
|
Richard Hollis, Chairman, President and CEO of Hollis-Eden Pharmaceuticals Talks to The Wall Street Transcript |
| 11/07/08 |
|
Hollis-Eden Pharmaceuticals Updates Upcoming Investor Conference Presentations and Webcasts |
| 11/06/08 |
|
Hollis-Eden Pharmaceuticals Provides Update on Clinical Development Programs; Announces Third Quarter 2008 Financial Results |
| 10/15/08 |
|
Hollis-Eden Pharmaceuticals to Webcast Investor Conference Presentations and Third Quarter 2008 Conference Call |
| 09/29/08 |
|
Hollis-Eden Pharmaceuticals Presents Additional Positive Findings for APOPTONE(TM) (HE3235) in Preclinical Models of Castration-Resistant Prostate Cancer |
| 09/25/08 |
|
Hollis-Eden Pharmaceuticals Presents Positive Updated Data from Phase I/II Clinical Trial with TRIOLEX(TM) in Obese Insulin Resistant Subjects |
| 09/12/08 |
|
Hollis-Eden Pharmaceuticals Reports Update on Autoimmunity Program with TRIOLEX(TM) (HE3286) at International Autoimmunity Meeting |
| 09/11/08 |
|
Hollis-Eden Pharmaceuticals to Present at the Merriman Curhan Ford 5th Annual Investor Summit |
| 08/07/08 |
|
Hollis-Eden Pharmaceuticals Reports on Progress in Drug Development Programs; Announces Second Quarter 2008 Financial Results |
| 08/05/08 |
|
Hollis-Eden Pharmaceuticals Commences Phase I/II Clinical Trial with TRIOLEX(TM) (HE3286) in Rheumatoid Arthritis Patients |
| 08/01/08 |
|
Hollis-Eden Pharmaceuticals Announces Conference Call and Webcast on Second Quarter 2008 Results and Drug Development Programs |
| 07/30/08 |
|
Hollis-Eden Pharmaceuticals Commences Phase I/II Clinical Trial with APOPTONE(TM) (HE3235) in Late-Stage Prostate Cancer Patients |
| 07/16/08 |
|
Hollis-Eden Pharmaceuticals Commences Phase II Clinical Trial with TRIOLEX(TM) (HE3286) in Type-2 Diabetes Patients; Expands Sites to Accelerate Enrollment |
| 06/09/08 |
|
Hollis-Eden Pharmaceuticals Reports Additional Positive Data from Phase I/II Clinical Trial with TRIOLEX(TM) Supporting Anti-Inflammatory Approach to Treating Type 2 Diabetes |
| 05/13/08 |
|
Hollis-Eden Pharmaceuticals Provides Update on Clinical Development Programs; Announces First Quarter 2008 Financial Results |
| 05/12/08 |
|
Hollis-Eden Pharmaceuticals to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference |
| 05/07/08 |
|
Hollis-Eden Pharmaceuticals Schedules First Quarter 2008 Conference Call and Webcast |
| 04/14/08 |
|
Hollis-Eden Pharmaceuticals Presents Positive Data with APOPTONE(TM) in Preclinical Bone Model of Late-Stage Prostate Cancer |
| 03/18/08 |
|
Hollis-Eden Pharmaceuticals Reports Positive Preliminary Data from Ongoing Phase I/II Clinical Trial with TRIOLEX(TM) in Obese Insulin Resistant Subjects |
| 03/17/08 |
|
Hollis-Eden Pharmaceuticals Provides Update on Clinical Development Program; Announces Fourth Quarter and Year-End 2007 Financial Results |
| 03/11/08 |
|
Hollis-Eden Pharmaceuticals Announces Conference Call and Webcast on Fourth Quarter 2007 Financial Results and Drug Development Programs |
| 02/19/08 |
|
Hollis-Eden Pharmaceuticals Announces Filing of IND with APOPTONE(TM) in Hormone Sensitive Cancers to Commence Phase I/II Clinical Trial in Late-Stage Prostate Cancer |
| 02/07/08 |
|
Hollis-Eden Pharmaceuticals Commences Phase I/II Clinical Trial in Ulcerative Colitis with Novel Oral Anti-Inflammatory Drug Candidate TRIOLEX(TM) |
| 02/05/08 |
|
Hollis-Eden Pharmaceuticals Presents Additional Data Demonstrating Activity of APOPTONE(TM) in Inducing Cancer Cell Death |
| 02/04/08 |
|
Hollis-Eden Pharmaceuticals to Present at 2008 BIO CEO and Investor Conference |
| 12/20/07 |
|
Hollis-Eden Pharmaceuticals Announces Cystic Fibrosis Foundation Therapeutics Selects TRIOLEX(TM) (HE3286) as a Next-Generation Oral Anti-Inflammatory Drug Candidate |
| 12/03/07 |
|
Hollis-Eden Pharmaceuticals to Present at the New York Society Of Security Analysts Biotech & Specialty Pharma Conference |
| 11/19/07 |
|
Hollis-Eden Pharmaceuticals Presents Data Demonstrating TRIOLEX(TM) Provides Benefit in Additional Animal Model of Rheumatoid Arthritis |
| 11/12/07 |
|
Hollis-Eden Pharmaceuticals Presents Data on APOPTONE(TM) and Potential Role of Adrenal Steroid Hormones for the Treatment of Cancer |
| 11/02/07 |
|
Hollis-Eden Pharmaceuticals Provides Update on Clinical Development Program; Announces Third Quarter 2007 Financial Results |
| 10/29/07 |
|
Hollis-Eden Pharmaceuticals Announces Conference Call and Webcast on Third Quarter 2007 Financial Results and Drug Development Programs |
| 10/16/07 |
|
Hollis-Eden Pharmaceuticals Commencing Phase I/II Clinical Trial with TRIOLEX(TM) (HE3286) in Obese, Insulin Resistant Volunteers |
| 10/09/07 |
|
Hollis-Eden Pharmaceuticals Announces Investor Presentations and Webcasts |
| 10/08/07 |
|
Hollis-Eden Pharmaceuticals Presents Positive Data Demonstrating HE3286 Provides Benefit in Animal Model of Ulcerative Colitis |
| 10/04/07 |
|
Hollis-Eden Pharmaceuticals Presents Positive Results with Novel Drug Candidate HE3235 in Model of Hormone Independent Prostate Cancer |
| 09/17/07 |
|
Hollis-Eden Pharmaceuticals Announces Filing of IND for Phase I/II Clinical Trials with HE3286 in Diseases of Inflammation |
| 09/14/07 |
|
Hollis-Eden Pharmaceuticals Announces Schedule of Upcoming Investor Presentations and Webcasts |
| 09/12/07 |
|
Hollis-Eden Pharmaceuticals Reports on Anti-Inflammatory Activity with HE3286 in Models of Diseases of Inflammation |
| 09/07/07 |
|
Hollis-Eden Pharmaceuticals Presents HE3235 Update at ASCO Breast Cancer Symposium |
| 08/03/07 |
|
Hollis-Eden Pharmaceuticals Reports on Progress in Drug Development Programs; Announces Second Quarter 2007 Financial Results |
| 08/02/07 |
|
Hollis-Eden Pharmaceuticals Names Scott M. Freeman, M.D., Chief Medical Officer |
| 07/30/07 |
|
Hollis-Eden Pharmaceuticals Announces Conference Call and Webcast on Second Quarter 2007 Financial Results and Drug Development Programs |
| 07/16/07 |
|
Hollis-Eden Pharmaceuticals Reports Initial Results in Phase I Clinical Trial of HE3286 as New Type II Diabetes Treatment |
| 05/07/07 |
|
Hollis-Eden Pharmaceuticals to Present at Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference |
| 05/04/07 |
|
Hollis-Eden Pharmaceuticals Announces Financial Results for First Quarter 2007 |
| 05/01/07 |
|
Hollis-Eden Pharmaceuticals Cleared by FDA to Initiate Phase I Clinical Trial with HE3286 in Treating Metabolic Disorders |
| 04/27/07 |
|
Hollis-Eden Pharmaceuticals Announces Reorganization |
| 04/26/07 |
|
Hollis-Eden Pharmaceuticals Announces First Quarter 2007 Conference Call and Webcast |
| 03/29/07 |
|
Hollis-Eden Pharmaceuticals Announces Filing of IND for Phase I Clinical Trial with Next-Generation Drug Candidate HE3286 in Metabolic Disorders |
| 03/16/07 |
|
Hollis-Eden Pharmaceuticals Announces Fourth Quarter and Year-End 2006 Financial Results |
| 03/13/07 |
|
Hollis-Eden Pharmaceuticals Announces Conference Call and Webcast on Fourth Quarter and Year-End 2006 Financial Results |
| 03/08/07 |
|
Hollis-Eden Announces Cancellation of Acute Radiation Syndrome RFP by Department of Health and Human Services |
| 02/26/07 |
|
Hollis-Eden Pharmaceuticals Reports Publication of Results Demonstrating the Ability of NEUMUNE(R) to Increase Survival in a Primate Model of Lethal Radiation Injury |
| 02/22/07 |
|
Hollis-Eden Pharmaceuticals Presents Additional Positive Data with Novel Steroid Hormone in Models of Prostate and Breast Cancer |
| 02/05/07 |
|
Hollis-Eden Pharmaceuticals to Present at 2007 BIO CEO and Investor Conference |
| 02/02/07 |
|
Hollis-Eden Pharmaceuticals Presents Positive Data with HE3286 in Preclinical Model of Established Rheumatoid Arthritis |
| 02/01/07 |
|
Hollis-Eden Pharmaceuticals Provides Update on Negotiations for BioShield Procurement Contract for NEUMUNE(R) as a Treatment for Acute Radiation Syndrome |
| 01/16/07 |
|
Hollis-Eden Pharmaceuticals Presents Data Demonstrating Discovery of an Endogenous Hormone Potentially Central to Glucose Metabolism |
| 11/30/06 |
|
Hollis-Eden Pharmaceuticals Presents Additional Positive Data with Drug Candidate HE3286 in Model of Rheumatoid Arthritis |
| 11/08/06 |
|
Hollis-Eden Pharmaceuticals to Raise $26.0 Million Through Sale of Common Stock and Warrants |
| 11/03/06 |
|
Hollis-Eden Pharmaceuticals Announces Third Quarter 2006 Financial Results |
| 11/03/06 |
|
Hollis-Eden Pharmaceuticals Provides Update on Final Stages of Negotiations for BioShield Procurement Contract |
| 11/01/06 |
|
Hollis-Eden Pharmaceuticals Announces Third Quarter 2006 Conference Call and Investor Conference Webcasts |
| 10/13/06 |
|
Hollis-Eden Pharmaceuticals Presents New Clinical Data That Support Use of NEUMUNE in Mitigating Acute Radiation Syndrome and Healthcare-Associated Infections |
| 10/12/06 |
|
Hollis-Eden Pharmaceuticals Announces Webcast of Presentation at BIO Investor Forum 2006 |
| 10/02/06 |
|
Hollis-Eden Pharmaceuticals Provides Update on Bone Marrow Regeneration Program and Chemotherapy Indication |
| 09/27/06 |
|
Hollis-Eden Pharmaceuticals Grants Extension of Offer to Department of Health and Human Services for Acute Radiation Syndrome Candidate |
| 09/13/06 |
|
Hollis-Eden Pharmaceuticals Presents Positive Preclinical Data on Compounds Targeting Hormone Refractory Prostate Cancer |
| 09/12/06 |
|
Hollis-Eden Pharmaceuticals Presents Data Demonstrating Potential Therapeutic Benefits of Second-Generation Drug Candidates |
| 08/04/06 |
|
Hollis-Eden Pharmaceuticals Announces Second Quarter 2006 Financial Results |
| 07/31/06 |
|
Hollis-Eden Pharmaceuticals Announces Second Quarter 2006 Conference Call and Investor Conference Webcasts |
| 06/26/06 |
|
Hollis-Eden Pharmaceuticals Provides Update on Status of NEUMUNE RFP for Acute Radiation Syndrome |
| 06/16/06 |
|
Hollis-Eden Pharmaceuticals Files Shelf Registration Statement |
| 06/16/06 |
|
Hollis-Eden Pharmaceuticals Presents Positive Preclinical Data on Orally Active Anti-Inflammatory Steroids Developed for Treatment of Lung Inflammation |
| 06/14/06 |
|
Hollis-Eden Pharmaceuticals to Present at Rodman & Renshaw 3rd Annual Security, Biodefense & Connectivity Investor Conference |
| 06/08/06 |
|
Hollis-Eden Pharmaceuticals Announces FDA Clearance to Commence Human Clinical Study with NEUMUNE in Patients at Risk of Healthcare-Associated Infections |
| 05/10/06 |
|
Hollis-Eden Pharmaceuticals Announces Financial Results for First Quarter 2006 |
| 05/04/06 |
|
Hollis-Eden Pharmaceuticals Announces First Quarter 2006 Conference Call and Investor Conference Webcasts |
| 05/03/06 |
|
Hollis-Eden Announces Filing of IND for Phase I Clinical Trials with NEUMUNE in Patients at Risk of Hospital-Acquired Infections |
| 03/16/06 |
|
Hollis-Eden Pharmaceuticals Announces Fourth Quarter and Year-End 2005 Financial Results |
| 03/13/06 |
|
Hollis-Eden Pharmaceuticals Announces Conference Call and Webcast on Fourth Quarter 2005 Financial Results |
| 02/24/06 |
|
Hollis-Eden Pharmaceuticals Submits Proposal in Response to Department of Health and Human Services Solicitation for Acute Radiation Syndrome (ARS) Therapy |
| 02/14/06 |
|
Hollis-Eden Pharmaceuticals Updates Investor Conference Schedule |
| 02/09/06 |
|
Hollis-Eden Pharmaceuticals to Present at BIO CEO and Investor Conference 2006 |
| 02/02/06 |
|
Hollis-Eden Pharmaceuticals to Raise $26.0 Million Through Sale of Common Stock and Warrants |
| 02/01/06 |
|
Hollis-Eden Pharmaceuticals Issues Notice Pursuant to NASDAQ Marketplace Rule 4803(a) |
| 01/31/06 |
|
Hollis-Eden Pharmaceuticals Responds to Sources Sought Notice from Department of Defense for Acute Radiation Syndrome Therapy for U.S. Forces |
| 01/10/06 |
|
Hollis-Eden Pharmaceuticals Advises Department of Health and Human Services of Intent to Respond to Request for Proposal (RFP) For Acute Radiation Syndrome (ARS) Therapy |
| 12/15/05 |
|
Hollis-Eden Pharmaceuticals Announces Decision In Arbitration |
| 11/03/05 |
|
Hollis-Eden Announces Third Quarter 2005 Financial Results |
| 11/01/05 |
|
Hollis-Eden Pharmaceuticals Releases Response to Department of Health and Human Services Draft Request for Proposal For Acute Radiation Syndrome Therapy |
| 10/31/05 |
|
Hollis-Eden Pharmaceuticals Announces Third Quarter 2005 Conference Call and Investor Conference Webcast |
| 10/18/05 |
|
Hollis-Eden Presents Positive Data from Preclinical and Clinical Studies with NEUMUNE |
| 10/17/05 |
|
Hollis-Eden Pharmaceuticals to Present at Investor and Scientific Conferences |
| 09/30/05 |
|
Hollis-Eden Comments on Issuance by the Department of Health and Human Services of Statement of Work for Acute Radiation Syndrome |
| 08/02/05 |
|
Hollis-Eden Announces Second Quarter 2005 Financial Results |
| 07/29/05 |
|
Hollis-Eden Pharmaceuticals Announces Webcasts on Second Quarter 2005 Conference Call and Corporate Presentation at Adams Harkness 25th Annual Summer Seminar |
| 07/08/05 |
|
Hollis-Eden Pharmaceuticals Files Shelf Registration Statement; Hollis-Eden Withdraws Previous Shelf Registration Statement |
| 07/05/05 |
|
Hollis-Eden Announces FDA Clearance to Commence Human Clinical Studies with NEUMUNE in the United States |
| 06/01/05 |
|
Hollis-Eden Pharmaceuticals Announces $10.0 Million Financing |
| 05/31/05 |
|
Hollis-Eden Announces Filing of an IND for NEUMUNE in the United States; HHS Anticipates Releasing Draft RFP by July 2005 for Therapeutics to Treat Acute Radiation Syndrome as Medical Countermeasures to Nuclear Terrorism |
| 05/10/05 |
|
Hollis-Eden Announces Financial Results for First Quarter 2005 |
| 05/04/05 |
|
Hollis-Eden Pharmaceuticals Announces Conference Call and Webcast on First Quarter 2005 Financial Results |
| 04/26/05 |
|
Hollis-Eden Pharmaceuticals to Present at Rodman & Renshaw Global Healthcare Conference |
| 04/05/05 |
|
Hollis-Eden Pharmaceuticals Announces Potent, Second-Generation Compounds Provide Significant Therapeutic Benefit in Preclinical Models of Lung Inflammation, Septic Shock and Multiple Sclerosis |
| 04/01/05 |
|
Hollis-Eden Announces Initiation of Phase I Clinical Study with NEUMUNE |
| 03/10/05 |
|
Hollis-Eden Pharmaceuticals to Present at SG Cowen & Co. 25th Annual Healthcare Conference |
| 03/08/05 |
|
Hollis-Eden Pharmaceuticals Announces Financial Results for Fourth Quarter and Year-End 2004 |
| 03/03/05 |
|
Hollis-Eden Pharmaceuticals Announces Conference Call and Webcast to Review Year-End 2004 Financial Results |
| 02/17/05 |
|
Hollis-Eden Pharmaceuticals CEO to Participate in Global Disease Funding Panel and Deliver Corporate Presentation at BIO CEO & Investor Conference 2005 |
| 12/21/04 |
|
Hollis-Eden Provides Update on NEUMUNE Development Program in Acute Radiation Syndrome |
| 11/09/04 |
|
Hollis-Eden Announces Financial Results for Third Quarter 2004 |
| 11/04/04 |
|
Hollis-Eden Pharmaceuticals Describes New Data with Potent Second Generation Immune Regulating Hormones in Preclinical Models of Autoimmune and Inflammatory Conditions |
| 11/03/04 |
|
Hollis-Eden Pharmaceuticals Announces Conference Call and Webcast to Review Third Quarter 2004 Financial Results |
| 10/22/04 |
|
Hollis-Eden Announces Plans to Respond to Department of Health and Human Services' Request for Information — RFI |
| 10/04/04 |
|
Hollis-Eden Releases Data from NEUMUNE Study Indicating Survival Benefit against High-Dose Radiation Exposure |
| 09/24/04 |
|
Hollis-Eden Pharmaceuticals Names Steven Gordziel Vice President, Product Development |
| 09/23/04 |
|
Hollis-Eden Pharmaceuticals Announces Upcoming Investor and Scientific Conference Presentations |
| 08/09/04 |
|
Hollis-Eden Announces Financial Results for Second Quarter 2004 |
| 08/03/04 |
|
Hollis-Eden Pharmaceuticals Announces Conference Call and Webcast to Review Second Quarter 2004 Financial Results |
| 07/21/04 |
|
Hollis-Eden Pharmaceuticals CEO Scheduled to Testify on WMD Medical Countermeasures before House Armed Services Committee |
| 07/01/04 |
|
Hollis-Eden Pharmaceuticals Reports New Option Grants Under Nasdaq Market Rule 4350 |
| 06/16/04 |
|
Hollis-Eden Pharmaceuticals Names Jessie Groothuis, M.D., Vice President, Clinical Affairs |
| 06/07/04 |
|
Hollis-Eden Pharmaceuticals Presents Additional Positive Data from Its Bone Marrow Protection Program; Results Presented at American Society of Clinical Oncology Meeting |
| 06/03/04 |
|
Hollis-Eden Pharmaceuticals to Be Biodefense Panel Participant and Corporate Presenter at BIO 2004 |
| 05/19/04 |
|
Hollis-Eden Pharmaceuticals to Present at the UBS 2004 Global Specialty Pharmaceuticals Conference |
| 05/07/04 |
|
Hollis-Eden Announces Financial Results for First Quarter 2004; Names Two New Nominees to the Company's Board of Directors |
| 05/05/04 |
|
Hollis-Eden Pharmaceuticals to Present at Rodman & Renshaw Techvest Global Healthcare Conference |
| 05/03/04 |
|
Hollis-Eden Pharmaceuticals Announces Conference Call and Webcast to Review First Quarter 2004 Financial Results |
| 03/15/04 |
|
Hollis-Eden Announces Financial Results for Fourth Quarter and Year-End 2003 |
| 03/10/04 |
|
Hollis-Eden Pharmaceuticals Announces Conference Call and Webcast to Review Year-End 2003 Financial Results |
| 03/05/04 |
|
Hollis-Eden Pharmaceuticals to Present at SG Cowen's 24th Annual Health Care Conference |
| 03/03/04 |
|
Hollis-Eden Pharmaceuticals Presents New Data on Molecular Mechanism of Action for HE2000; Data Presented at the Strategies for Immune Therapy Meeting |
| 03/01/04 |
|
Hollis-Eden Pharmaceuticals To Present At RedChip Resources and Moors & Cabot, Inc. Investor Conference |
| 02/25/04 |
|
Hollis-Eden Announces Acquisition of Congressional Pharmaceutical; Provides Additional Product Opportunity in Radiation Protection |
| 02/19/04 |
|
Hollis-Eden Pharmaceuticals To Webcast Presentation At BIO CEO & Investor Conference 2004 |
| 12/08/03 |
|
Hollis-Eden Pharmaceuticals Announces Positive Results in Models of Radiation and Chemotherapy-Induced Neutropenia with Investigational Immune Regulating Hormones |
| 11/04/03 |
|
Hollis-Eden Announces Results of Clinical Trial with HE2200 in Patients with Dyslipidemia |
| 10/16/03 |
|
Hollis-Eden Pharmaceuticals to Webcast Rodman & Renshaw Techvest Healthcare Conference Presentation |
| 10/06/03 |
|
Hollis-Eden Pharmaceuticals Announces Notice of Allowable Patent Claims by European Patent Office for Improved Form of HE2000 |
| 10/02/03 |
|
Pacific Exchange to Trade Three New Options |
| 10/01/03 |
|
Hollis-Eden Pharmaceuticals Closes Public Offering of Common Stock |
| 09/26/03 |
|
Hollis-Eden Pharmaceuticals Prices $62.5 Million Follow-On Offering of Common Stock |
| 09/19/03 |
|
Hollis-Eden Pharmaceuticals Announces Webcast of Presentation at UBS Global Life Sciences Conference |
| 09/04/03 |
|
Hollis-Eden Pharmaceuticals to Present at Roth Capital Partners Conference |
| 08/11/03 |
|
Hollis-Eden Pharmaceuticals Converts Debentures into Common Stock |
| 07/24/03 |
|
Hollis-Eden Pharmaceuticals Files Shelf Registration Statement; Withdraws Previous Shelf Registration Statement |
| 07/24/03 |
|
Hollis-Eden Pharmaceuticals Names Scott A. Rieger Director of Corporate Communications |
| 07/01/03 |
|
Hollis-Eden Pharmaceuticals Added to Russell 3000 and 2000 Indexes |
| 06/23/03 |
|
Hollis-Eden Pharmaceuticals To Present At Bio 2003 Annual Convention; Webcast Available At Company's Website |
| 06/23/03 |
|
Hollis-Eden Pharmaceuticals Presents Data Demonstrating Statistically Significant Reduction in Opportunistic Infections in Late Stage Aids Patients Treated With HE2000 |
| 06/20/03 |
|
Hollis-Eden Pharmaceuticals Completes $15 Million Private Placement |
| 06/18/03 |
|
Hollis-Eden Pharmaceuticals and the Cystic Fibrosis Foundation to Collaborate on Clinical Development of HE2000 in Cystic Fibrosis |
| 06/05/03 |
|
Hollis-Eden Announces Patent Granted from European Patent Office for Cancer Drug Candidate |
| 05/16/03 |
|
Hollis-Eden Names Jerry Englert as Director of Strategic Planning and Financial Relations |
| 05/06/03 |
|
Hollis-Eden Pharmaceuticals Presents Data Correlating Hormone Structure to Specific Immune Regulating Activity |
| 04/29/03 |
|
Hollis-Eden Pharmaceuticals Presents Additional Tuberculosis Data Supporting Broad-Spectrum Use of Immune Regulating Hormones in Infectious Diseases and Biodefense |
| 04/07/03 |
|
Hollis-Eden Pharmaceuticals Announces HE2100 Provides Significant Protection from Radiation in Primate Study |
| 03/17/03 |
|
Hollis-Eden Pharmaceuticals to Present at SG Cowen Health Care Conference; Webcast Available at Company's Website |
| 03/14/03 |
|
Hollis-Eden Pharmaceuticals Announces Financial Results for Year 2002 |
| 02/26/03 |
|
Hollis-Eden Pharmaceuticals Raises $10 Million |
| 02/24/03 |
|
Hollis-Eden Pharmaceuticals to Present at BIO CEO Investor Conference; Webcast Available at Company's Website |
| 02/03/03 |
|
Hollis-Eden Announces Grant Awarded by the Office of Naval Research to Study HE2200 In the Treatment of Traumatic Shock |
| 01/27/03 |
|
Hollis-Eden Announces Patent Granted for HE2100 and HE2200 in Japan |
| 01/14/03 |
|
Hollis-Eden and Walter Reed Army Research Institute to Test Immune Regulating Hormones Against Bioterrorism Agents |
| 12/19/02 |
|
Hollis-Eden Announces Patent Granted for Anti-Radiation Drug Candidate From European Patent Office |
| 12/05/02 |
|
Hollis-Eden Pharmaceuticals Releases Letter by South African Government Calling for Broad Support of its Phase III Drug Candidate in HIV, Infectious Disease |
| 12/02/02 |
|
Hollis-Eden Recieves Notice of New Allowable Claims for HE2000 From U.S. Patent & Trademark Office; New Composition for Improved Crystal Structure |
| 11/21/02 |
|
Hollis-Eden Reports Positive Results From Malaria Phase II Clinical Trial With Buccal Formulation of HE2000 |
| 11/20/02 |
|
Hollis-Eden Reports Positive Effects of Immune Regulating Hormones in Primate Model of Chemotherapy Protection |
| 11/15/02 |
|
Hollis-Eden Selected to Present At the BIO/Bill and Melinda Gates Foundation Partnering for Global Health Forum |
| 10/25/02 |
|
Hollis-Eden Pharmaceuticals Announces Update On Collaboration with Aeson Therapeutics, Inc. |
| 09/18/02 |
|
Hollis-Eden to Discuss Public/Private Partnerships at Commonwealth Business Forum |
| 09/10/02 |
|
Hollis-Eden Announces Publication of Results Showing Benefit of Immune Regulating Hormone Therapy in Preclinical Model of Multiple Sclerosis |
| 08/29/02 |
|
Hollis-Eden Licenses Patents from Pharmadigm, Inc. |
| 08/05/02 |
|
Hollis-Eden Cleared By FDA To Initiate Phase II Clinical Trial With HE2200 In Patients With Elevated Cholesterol |
| 08/02/02 |
|
Corporate Profile for Hollis-Eden Pharmaceuticals, dated Aug. 2, 2002 |
| 07/22/02 |
|
Hollis-Eden Pharmaceuticals Announces HE2200 Significantly Increases Survival in Preclinical Model of Lupus |
| 07/08/02 |
|
Hollis-Eden Pharmaceuticals Presents Additional Clinical Data With HE2000 In HIV Infected Patients; Data Presented at XIV World AIDS Conference |
| 05/15/02 |
|
Hollis-Eden Pharmaceuticals Announces HE2500 Significantly Reduces Inflammation in Preclinical Model of Arthritis |
| 05/06/02 |
|
Hollis-Eden Pharmaceuticals Announces HE2500 Significantly Reduces Triglycerides in Patients With Lipid Disorders |
| 04/23/02 |
|
REPEAT/Hollis-Eden Pharmaceuticals Announces HE2500 Significantly Reduces Ongoing Paralysis and Accelerates Recovery in Preclinical Model of Multiple Sclerosis |
| 04/23/02 |
|
Hollis-Eden Pharmaceuticals Announces HE2500 Significantly Reduces Ongoing Paralysis and Accelerates Recovery in Preclinical Model of Multiple Sclerosis |
| 04/22/02 |
|
Hollis-Eden Pharmaceuticals Announces HE2100 Stimulates Innate Immunity in Preclinical Model of Radiation Injury |
| 04/10/02 |
|
Hollis-Eden Initiates Phase I/II Clinical Trial With HE2200 for Vaccine Potentiation |
| 03/12/02 |
|
Hollis-Eden Pharmaceuticals Scheduled to Give Counter-Terrorism Testimony Before House Armed Services Subcommittee |
| 02/26/02 |
|
Hollis-Eden Pharmaceuticals Announces Financial Results for Year 2001 |
| 02/21/02 |
|
Hollis-Eden Pharmaceuticals Presents Anti-Inflammatory Effects of HE2500 in Preclinical Model of Psoriasis; Data Presented At Third International Congress On Autoimmunity |
| 02/19/02 |
|
Hollis-Eden Pharmaceuticals to Present At Roth Capital Partners and BIO CEO Investor Conferences |
| 02/14/02 |
|
Multimedia Available: Department of Defense Medical School and Hollis-Eden Form Collaboration to Develop Drug for Protection Against Radiation Damage |
| 02/14/02 |
|
Department of Defense Medical School and Hollis-Eden Form Collaboration to Develop Drug for Protection Against Radiation Damage |
| 12/13/01 |
|
Hollis-Eden Completes $11.5 Million Private Placement |
| 11/26/01 |
|
Hollis-Eden Completes Initial Phase I Clinical Study with HE2200 |
| 11/12/01 |
|
Malaria Parasites Cleared in Patients With Hollis-Eden Pharmaceuticals Immune Regulating Hormone |
| 11/08/01 |
|
Hollis-Eden Pharmaceuticals Presents Anti-Inflammatory Effects Of Immune Regulating Hormones |
| 10/04/01 |
|
Hollis-Eden Pharmaceuticals Cleared to Initiate Clinical Trial in Hepatitis B; The Company Initiates Dosing HE2000 in Malaria Patients |
| 09/14/01 |
|
Hollis-Eden Enters Into Agreement for $10MM Stock Equity Line; Company Also Announces Updated Website |
| 09/10/01 |
|
Hollis-Eden Presents Data Demonstrating HE2000 Regulates a Broad Array of Inflammatory Mediators Implicated in Disease Progression in HIV Patients |
| 09/04/01 |
|
Hollis-Eden Pharmaceuticals Appoints Director of Tumor and Vaccine Immunology |
| 08/16/01 |
|
Hollis-Eden Pharmaceuticals Appoints Scientific Investigator for Allergy, Autoimmunity and Inflammation |
| 06/29/01 |
|
Hollis-Eden Receives FDA Clearance to Initiate Human Clinical Studies With HE2200 |
| 06/18/01 |
|
Hollis-Eden Pharmaceuticals, Inc. To Present at RedChip Investor Conference Thursday, June 21, 2001, at 6:00 p.m. ET -3:00 p.m. PT- |
| 06/01/01 |
|
Hollis-Eden Pharmaceuticals to Present at the Wall Street Analyst Forum On June 5, 2001; Webcast Available
|
